Rebeccamycin is a novel indolocarbazole topoisomerase I inhibitor.
Rebeccamycin is an indolocarbazole isolated from Lechevalieria aerocolonigenes. Rebeccamycin displays selective antitumour activity against several cell lines. Rebeccamycin's primary mechanism of action is via strong DNA intercalation resulting in the potent catalytic inhibition of both topoisomerases I and II. Analogues of rebecamycin have beend tested in clinical trials for cancer therapy.
ChEBI: An N-glycosyl compound consisting of a heteropolycyclic ring system with a glucosyl group attached to one of the indolic nitrogens.
Rebeccamycin (2-256 mg/kg; i.p.; daily for 9 days) prolongs survival in B16 melanoma, L1210 leukemia[2].
| Animal Model: | CDF1 mice (B16 melanoma, L1210 leukemia)[2] |
| Dosage: | 2, 4, 8, 16, 32, 64, 128, 256 mg/kg |
| Administration: | I.p.; daily for 9 days |
| Result: | Prolongation of survival of the mice at dose levels ranging from 8 to 256 mg/kg. |
Topoisomerase I; Traditional Cytotoxic Agents
